Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials
Final published version, 361 KB, PDF document
| Original language | English |
|---|---|
| Journal | British Journal of Dermatology |
| Volume | 181 |
| Issue number | 5 |
| Pages (from-to) | 967-975 |
| ISSN | 0007-0963 |
| DOIs | |
| Publication status | Published - 2019 |
Number of downloads are based on statistics from Google Scholar and www.ku.dk
No data available
ID: 240427884